Insights Center

Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.

Featured

Mintz Direct

On our new Mintz Direct page, Mintz thought leaders across industries and practice areas offer timely insights on developments that impact our clients and communities. Visit the Mintz Direct page to hear what our experienced attorneys and professionals are saying about what’s happening now.

Mintz Viewpoints

Use quotation marks to search for an exact phrase (e.g. “class action”)

Published

Showing 2929 - 2936 of 12127 results

The Road Less Travelled: Why Arbitration is an Increasingly Attractive Alternative for Resolving IP Disputes

September 26, 2021| Blog| Viewpoint

What We’re Reading – September 24, 2021

September 24, 2021| Blog| Viewpoint

Industry’s Touting Of Citizen Suit Standing Hurdles Appears ‘Optimistic’

September 24, 2021| News

Patent Owner Tip #18 for Surviving an Instituted IPR: Defending Depositions

September 23, 2021| Blog| Viewpoint

OIG Report Highlights Importance of Telehealth in Providing Behavioral Health Services, but Emphasizes Need for Additional Oversight

September 23, 2021| Blog| Viewpoint

The Impact of the ACA Employer Shared Responsibility Rules and Wellness Program Limits on COVID-19 Premium Surcharges

September 23, 2021| Blog| Viewpoint

California’s New Privacy Regulator Invites You to Comment

September 23, 2021| Blog| Viewpoint

Regulatory Fees for Unlicensed Users and Large Technology Companies?

September 22, 2021| Blog| Viewpoint

News & Press Releases

Mintz Advises on LB Pharmaceuticals’ $285 Million Initial Public Offering

September 12, 2025

Mintz advised the underwriters in connection with a $285 million initial public offering by LB Pharmaceuticals Inc of 19,000,000 shares of common stock at an initial public offering price of $15.00 per share. The aggregate gross proceeds to LB Pharmaceuticals from this offering were approximately $285 million before deducting underwriting discounts and commissions and other offering expenses. In addition, LB Pharmaceuticals granted the underwriters a 30-day option to purchase up to an additional 2,850,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The shares began trading on the Nasdaq Global Market on September 11, 2025 under the ticker symbol “LBRX.”

Mintz Advises Premier Wealth Advisor Breed’s Hill Capital on Acquisition by Corient

September 12, 2025

Mintz represented Breed’s Hill Capital, a multi-family office overseeing approximately $3.5 billion in assets, in its acquisition by Corient, one of the nation’s leading wealth management firms. The transaction enhances Corient’s footprint in New England and advances its ability to deliver personalized fiduciary wealth management services across the region.

Three Mintz Attorneys Recognized in Lawdragon’s 2025 500 Leading Global Real Estate Lawyers

September 11, 2025

Mintz members Daniel Guggenheim, Rebecca Lee, and Jeffrey Moerdler have been recognized by Lawdragon in its 2025 500 Leading Global Real Estate Lawyers list. The three attorneys were also recognized in last year’s inaugural edition of the list.

View all News and Press Releases